SciSparc Ltd. (SPRC) vs Virax Biolabs Group Limited (VRAX)
A side-by-side comparison of SciSparc Ltd. and Virax Biolabs Group Limited across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
SPRC
SciSparc Ltd.
$4.33HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
VRAX
Virax Biolabs Group Limited
$2.03HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — SPRC vs VRAX
growth of $100 · dividends reinvested · last 4ySPRC -99.9% (-84.9%/yr)VRAX -99.9% (-84.8%/yr)VRAX compounded faster over this window
SPRC VRAX
SPRC vs VRAX: by the numbers
- •VRAX is the larger company ($378849 vs $250443 market cap).
- •Both run net losses; SPRC's is the smaller (-1422.78% vs -40439.10% net margin).
- •SPRC grew revenue faster over the past five years (9.25% vs -36.87% CAGR).
Metrics side by side
Valuation
| Metric | SPRC | VRAX |
|---|---|---|
| P/B ratio | 0.06 | 0.05 |
Profitability
| Metric | SPRC | VRAX |
|---|---|---|
| Gross margin | 73.71% | 61.90% |
| Operating margin | -1022.08% | -51515.17% |
| Net margin | -1422.78% | -40439.10% |
| ROE | -287.31% | -66.30% |
| ROIC | -152.82% | -83.46% |
Growth (annualized)
| Metric | SPRC | VRAX |
|---|---|---|
| Revenue CAGR (5Y) | 9.25% | -36.87% |
| Total return CAGR (5Y) | -82.56% | N/A |
Frequently asked
- Which has grown faster, SPRC or VRAX?
- Over the past five years, SPRC grew revenue faster — SPRC at a 9.25% CAGR versus VRAX at -36.87%.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.